Please login to the form below

Not currently logged in
Email:
Password:

non-Hodgkin

This page shows the latest non-Hodgkin news and features for those working in and with pharma, biotech and healthcare.

CTI slumps as Servier-partnered lymphoma drug fails

CTI slumps as Servier-partnered lymphoma drug fails

CTI BioPharma has been poleaxed by the news that its much-anticipated late-stage trial for Pixuvri in non-Hodgkin’s lymphoma (NHL) has ended in failure.

Latest news

More from news
Approximately 16 fully matching, plus 138 partially matching documents found.

Latest Intelligence

  • Deal Watch November 2016 Deal Watch November 2016

    relapsed or refractory aggressive CD19+ Non-Hodgkin Lymphoma. ... acquisition - company. 235. Idera Pharmaceuticals/ Vivelix Pharmaceuticals. IMO-9200, antagonist of TLR 7, 8 and 9, for non-malignant GI disorders (p1) back ups.

  • Deal Watch June 2016 Deal Watch June 2016

    on B-cell tumor cells, including chronic lymphocytic leukaemia (CLL) and non-Hodgkin lymphoma (NHL) cells). ... Tiered mid single digit. Non-exclusive rights to XmAb Fc technology for up to 10 molecules.

  • Astellas: Ten years young Astellas: Ten years young

    Meanwhile, the company has Levact (bendamustine) for chronic lymphocytic leukaemia, non-Hodgkin's lymphomas and multiple myeloma, giving it broader interests in the area.

  • Pharma deals in April 2015 Pharma deals in April 2015

    The initial non-binding proposal of $205 per share, approx. $28.9bn was rejected by Perrigo as a serious undervaluation. ... Under the terms of the deal, Celgene has the rights to develop the product for non-Hodgkin lymphoma (NHL), myelodysplastic

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    700. NGM Biopharmaceuticals/ Merck &Co. NP201 other preclinical candidates - diabetes, obesity, non-alcoholic steatohepatitis (NASH). ... CLL, chronic lymphocytic leukaemia; NHL, indolent non-Hodgkin lymphoma.

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Therapy Watch expands oncology and IBD portfolios

    Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer

  • Therapy Watch expands its oncology portfolio

    Therapy Watch SCCHN is part of a wider portfolio which covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer (PCa), Renal

  • Oncology drugs under AMNOG

    Pixuvri: Polycomparator segmentation by the G-BA removes statistical power. Cell Therapeutics gained European approval for Pixuvri (pixantrone) in non-Hodgkin’ s B-cell lymphoma, on the basis of a trial

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Four Health Media

Four Health Media creates world class integrated media solutions with global reach, deep insight, innovative methods and a highly personal...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics